GB:STX Stock Latest News
Company AnnouncementsShield Therapeutics updates total voting rights and share capital1M ago
Company AnnouncementsShield Therapeutics Updates Total Voting Rights as Iron Drug Growth Continues2M ago
Company AnnouncementsShield Therapeutics Takes Full Control of U.S. ACCRUFeR Business to Boost Profitability2M ago
Company AnnouncementsShield Therapeutics narrows losses as ACCRUFeR® growth and global milestones lift H1 revenue2M ago
Company AnnouncementsShield Therapeutics updates total voting rights and underscores global iron therapy push3M ago
Company AnnouncementsShield Therapeutics grows H1 revenue, pivots commercial strategy and appoints new CFO3M agoCompany AnnouncementsShield’s pediatric trial backs ferric maltol in childhood iron deficiency anemia3M ago
Company AnnouncementsShield Therapeutics issues shares under performance plan while keeping other incentive schemes unchanged4M ago
Company AnnouncementsShield Therapeutics Secures Strong Shareholder Backing at 2026 AGM4M ago- Company AnnouncementsShield Therapeutics updates share capital as iron deficiency franchise expands globally5M ago
Company AnnouncementsShield Therapeutics awards CEO new share options to support growth of iron drug franchise6M ago- Company AnnouncementsShield Therapeutics posts profitable Q1 as ACCRUFeR sales surge and CFO departs6M ago
Company AnnouncementsShield Therapeutics Updates Total Voting Rights and Highlights Global Iron Therapy Franchise6M agoCompany AnnouncementsShield Therapeutics Starts Japanese Phase II Trial of ACCRUFeR in Pulmonary Arterial Hypertension6M ago
Company AnnouncementsShield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 20256M ago
Company AnnouncementsShield Therapeutics Gains Pediatric Boost as Ferric Maltol Data Published in Leading Journal7M ago
Company AnnouncementsShield Therapeutics updates share capital and underscores global iron deficiency franchise7M ago
Company AnnouncementsShield Therapeutics gains EMA backing to extend FeRACCRU use to adolescents7M ago
Company AnnouncementsShield Therapeutics Advances ACCRUFeR Into China With NMPA Filing Acceptance8M agoCompany AnnouncementsShield Therapeutics Updates Voting Rights as Iron Drug Expansion Continues8M ago
Company AnnouncementsShield Therapeutics Wins Extra U.S. FDA Exclusivity for ACCRUFeR Pediatric Use8M ago
